Renal haemodynamics and sodium excretory capacity during urapidil treatment in patients with essential hypertension

Journal of Hypertension

Volumn 18, Issue 7, 2000, Pages 963-969

  Lavrijssen, Arie T J ^a   Kroon, Abraham A ^a   Fuss Lejeune, Monique ^a   Schiffers, Paul M H ^b   De Leeuw, Peter W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Aldosterone; Atrial natriuretic peptide; Renal haemodynamics; Sodium excretion; Urapidil

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CATECHOLAMINE DERIVATIVE; NEUROHORMONE; RENIN; SODIUM; URAPIDIL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE RESPONSE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM EXCRETION;

EID: 0033941525     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018070-00019     Document Type: Article

References (24)

1. 1 Van Zwieten PA, de Jonge A, Wilffert B, Timmermans PB, Beckeringh JJ, Thoolen MJ. Cardiovascular effects and interaction with adrenoceptors of urapidil. Arch Int Pharmacodyn Ther 1985; 276:180-201.
2. 2 Sanders KH, Beller KD, Bischler P, Kolassa N. Interaction of urapidil with brain serotonin-1A receptors increases the blood pressure reduction due to peripheral alpha-adrenoceptor inhibition. J Hypertens 1988; 6 (suppl 2):S65-S68.
3. 3 Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs 1998; 56:929-955.
4. 4 Bauer JH. Adrenergic blocking agents and the kidney. J Clin Hypertens 1985; 1:199-221.
5. 5 Krauss XH, Schalekamp MADH, Kolsters G, Zaal GA, Birkenhäger WH. Effects of chronic beta-adrenergic blockade on systemic and renal haemodynamic responses to hyperosmotic saline in hypertensive patients. Clin Sci 1972; 43:385-391.
6. 6 Schalekamp MADH, Krauss XH, Schalekamp-Kuyken MPA, Kolsters G, Birkenhäger WH. Studies on the mechanism of hypernatriuresis in essential hypertension in relation to measurements of plasma renin concentration, body fluid compartments and renal function. Clin Sci 1971; 41:219-231.
7. 7 Friberg P, Meredith I, Jennings G, Lambert G, Fazio V, Esler M. Evidence for increased renal norepinephrine overflow during sodium restriction in humans. Hypertension 1990; 16:121-130.
8. 8 Schnurr E, Lahme W, Küppers H. Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 1980; 13:26-29.
9. 9 De Leeuw PW, Kho TL, Falke HE, Birkenhäger WH, Wester A. Haemodynamic and endocrinological profile of essential hypertension. Acta Med Scand 1978; 622:9-86.
10. 10 Simon D, Hartmann DJ, Badouaille G, Caillot G, Guyenne TT, Corvol P, et al. Two-site direct immunoassay specific for active renin. Clin Chem 1992; 38:1959-1962.
11. 11 Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985; 7 (suppl 1):11-17.
12. 12 Kubasik NP, Warren K, Sine HE. Evaluation of a new commercial radioassay kit for aldosterone using an iodinated tracer. Clin Biochem 1978; 12:59-61.
13. 13 Van der Hoorn FA, Boomsma F, Man in 't Veld AJ, Schalekamp MADH. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr 1989; 487:17-28.
14. 14 Rosmalen FMA, Tan ACITL, Tan HS, Benraad TJ. A sensitive radioimmunoassay of atrial natriuretic peptide in human plasma, using a tracer with an immobilized glycouril agent. Clin Chim Acta 1987; 165:331-340.
15. 15 Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300:230-235.
16. 16 Birkenhäger WH, De Leeuw PW, Schalekamp MADH. Control mechanisms in essential hypertension. Amsterdam: Elsevier Biomedical Press; 1982.
17. 17 Simpson FO. Sodium intake, body sodium, and sodium excretion. Lancet 1988; 2:25-29.
18. 18 Gerber A, Weidmann P, Marone C, Uehlinger D, Riesen W. Cardiovascular and metabolic profile during intervention with urapidil in humans. Hypertension 1985; 7:963-971.
19. 19 Hirata Y, Hayakawa H, Suzuki E, Matsuoka H, Sugimoto T. Renal and endocrine effects of urapidil in patients with essential hypertension. Curr Ther Res 1991; 49:961-967.
20. 20 Kobrin I, Amodeo C, Ventura HO, Messerli FH, Frohlich ED. Immediate hemodynamic effects of urapidil in patients with essential hypertension. Am J Cardiol 1985; 55:722-725.
21. 21 De Leeuw PW, van Es PN, de Bruyn HAM, Birkenhäger WH. Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man. Drugs 1988; 35 (suppl 6):74-77.
22. 22 Wambach G, Godehardt E, Lang R, Heitz W, Meurer KA, Kaufmann W. Pharmacodynamics of urapidil in essential hypertension and in chronic renal failure. In: Amery A (editor): Treatment of hypertension with urapidil: preclinical and clinical update. London: Royal Society of Medicine Services; 1986. pp. 63-69.
23. 23 Leonetti G, Terzoli L, Rupoli L, Gradnik R, Zanchetti A. Effects of intravenous urapidil on blood pressure, renal plasma flow and responsiveness to vasoconstrictor agents in hypertensive patients. In: Amery A (editor): Treatment of hypertension with urapidil: preclinical and clinical update. London: Royal Society of Medicine Services; 1986. pp. 11-17.
24. +, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987; 31:135-141.